FDA Reopens Comment Period on Direct-to-Consumer Prescription Drug Advertisements

Summary

The FDA is reopening the comment period on proposed rules for direct-to-consumer prescription drug advertisements, allowing for public input on a new study that evaluates the impact of distractions on consumer understanding of risk and benefit information.